TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in Baroreflex sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cue-induced alcohol craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress-induced alcohol craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Terminal Phase Elimination Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fatigue Interference Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cortisol-ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of infectious events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects with dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility for CBT-I
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of TDP 43
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Tau assessed by Western blot and qPCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Opioid Abstinent Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Young Consumers' Sustainable Consumption Behaviors (YCSCB)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Ethically Minded Consumer Behavior (EMCB)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Major adverse limb event (MALE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Admission within 48 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Admission within 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Reproductive capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Target Range Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of IV drug use and sexual risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in bodyweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of KOA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Capsular bend index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toric IOL total axial deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total Lean Body Mass (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency rate of main and branch stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Difference in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Assessment of back function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Lumbar flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of the tablet game-based assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Weight (Percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functionality assessment using the Western Ontario and McMaster Universities Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual analogue score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in patient Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in patient Medical Outcomes Study Short Form-20 (SF-20)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pattern of congenital hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success rate of esophageal examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Serum Drug Concentration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydroxyurea adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: acute graft-vs-host disease (aGVHD) outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of interleukin 4(IL-4), interleukin 5(IL-5), interleukin 13(IL-13)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physiological Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants retained in the intervention arm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of target sample achieved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in maximum cavity wall thickness on CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline in PTSD Checklist-Military Version (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale - Leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance Wakefulness Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affected leg stance time treatment-change difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Each Gastrointestinal Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Presence of Non-gastrointestinal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve AUC (0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve AUC (0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First detection of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in stride time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound assessment using DMIST scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tear breaking rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of individuals who screen positive for pulmonary TB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of individuals who are diagnosed with pulmonary TB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Navigation performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Histological description of genital organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Low mood symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CSF leakage grade change after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sarcopenic obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Informed choice about cataract surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical neurological development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain MRI structural brain abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: average 24h blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of TYRA-200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal dose of TYRA-200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated intellectual functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Accuracy of the Belief That FDA Authorized COVID-19 Vaccines Are Safe and Effective
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Intention to Get a COVID-19 Vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Baseline prevalence of Staphylococcus aureus carriage or infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Combined incidence of GC, CT, and/or early syphilis infection
Endpoint domain: Adverse events/effects
Primary endpoint: Post-intervention TB sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: outcome of treatment for non traumatic chronic subdural haematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Relapse of endometrial cancer or EIN
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients safely de-labelled from penicillin allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic VAS score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in depression score on the PHQ-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent wound area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of small fiber neuropathy or pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eligibility for I-131 therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Health Related Quality of Life as Measured by Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health Related Quality of Life as Measured by University of California, Los Angeles (UCLA) Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Health Related Quality of Life as Measured by Functional Assessment of Cancer Therapy General - 7 Item Version (FACT-G7)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline at Day 28 in IDEEL-SB Question Sore
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline at Day 28 in IDEEL-SB Question Stinging
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline at Day 28 in IDEEL-SB Question Burning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline at Day 28 in IDEEL-SB Question Tired Eyes
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline at Day 28 in DEQ-5 Question Watery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in child BMI-for-age z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation of serum myokines with muscle mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of fasting insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline of triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in total sleep time (TST)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes from baseline in sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in REM sleep without atonia (RWA)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Muscle Soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shooting percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20-meter sprint test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum tryptase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue tryptase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability: Semi-structured Interview (Mentees)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adoption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility: Compliance with iPeer2Peer program (Mentees)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Preference for MK-3475A Subcutaneous
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Outcomes of digestive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of post-splenectomy infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate constant for tigecycline distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual's and parental view regarding management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration-time curve from zero to the last quantifiable concentration (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with treatment-emergent adverse event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Continuous measurement of burst suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive measurement of arterial stiffness by pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Continuous non-invasive measurement of mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Serum ALT (Alanine Aminotransferase) level at 3-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Serum ALT (Alanine Aminotransferase) level at 6-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Range of motion in flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Range of motion in extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Range of motion in rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Range of motion in side flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep Neck Flexor Endurance Test time held
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faces Pain Scale-Revize (FPS-R)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inflammatory markers (TNF-α, IL-1β, IL-6, IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarkers with protective functions (PGE2, NO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Insulin-like Growth Factor I (IGF-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: User acceptability of gel delivery system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total norepinephrine-requirement within 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total crystalloid volume-requirement within 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of protein-coding rare variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratometric astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chorioamnionitis or intraamniotic or intrauterine infection
Endpoint domain: Adverse events/effects
Primary endpoint: Intervention Delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intervention utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: YF neutralizing antibody (NAb) seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of patients achieving acceptable dose distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Discordance between fractional flow reserve and quantitative flow ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nicotine Product Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uv Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential gene expression in endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of heavy drinking days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Marginal bone loss measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient adherence to adjuvant endocrine therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement for sitting-lying position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement for sitting-standing transition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement for step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement for walking pace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) rate per Investigator assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune effector cell-associated neurotoxicity syndrome (ICANS) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence-free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incremental area under curve (iAUC 0-240 min) of postprandial glycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration from initiation of radiotherapy to onset of acute radiation esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of acute radiation esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of severe acute radiation esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Target Sedation Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen level dependent (BOLD) response to self-talk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen level dependent (BOLD) response to dyadic exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual-Object long-term memory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of indications for a second revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Active Range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional workspace
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Goal Attainment Scale (GAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Safety characterized by frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in long-term similarity of blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes